In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2011 Scrip 100: Taking drug regulation to a higher level

This article was originally published in Scrip

Executive Summary

The regulation of drug development is moving to a new level, driven by advances in science and the need to better assess the safety profile of new compounds. Regulators will soon be faced with products emerging from areas such as regenerative medicine, gene therapy, personalised or stratified medicine, and nanotechnology. Finding new tools to assess safety, efficacy and quality is vital if these discoveries are to be translated into commercial products.

You may also be interested in...



France Moves To Bolster Drug Supplies Hit By COVID-19

France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.

Belgium Imposes Selective Export Ban As COVID-19 Threatens Stocks

A number of countries are resorting to extreme measures such as export bans to preserve stocks of medicines for the COVID-19 pandemic. Belgium is among the latest to impose an export prohibition, but might it fall foul of the EU’s export regulations? 

Coronavirus Update: Supercomputing, Regulatory Flexibilities & Coordinating Supply Strategies

In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.

Topics

Related Companies

UsernamePublicRestriction

Register

SC011277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel